Sort by
Keyphrases
Clinical Trials
100%
Drug Development
100%
Risk Outcomes
100%
Patient Outcomes
100%
Patient Benefit
100%
Risk-benefit
100%
Patient Risk
100%
Lenvatinib
100%
FDA-approved Drugs
55%
Adverse Events
33%
Overall Survival
22%
Progression-free Survival
22%
Objective Response Rate
22%
Approved Indication
22%
Novel Indications
22%
Expanded Indication
22%
High Burden
11%
PubMed
11%
MEDLINE
11%
Embase
11%
Solid Tumors
11%
Cochrane
11%
Potential Gains
11%
Patient Experience
11%
Evidence Review
11%
Drug Efficacy
11%
Trial Characteristics
11%
Safety Profile
11%
Clinical Trial Results
11%
FDA Indications
11%
Adult Participants
11%
Adverse Event Data
11%
Solid Cancer
11%
Survival Response
11%
Clinical Trial Participant
11%
Non-randomized Clinical Trial
11%
Phase I Clinical Trial
11%
US FDA
11%
Phase II Clinical Trial
11%
Phase III Clinical Trial
11%
Benefit Ratio
11%
Failure to Progress
11%
Chemotherapy Agents
11%
Medicine and Dentistry
Clinical Trial
100%
Systematic Review
100%
Lenvatinib
100%
Adverse Event
33%
Malignant Neoplasm
16%
Progression Free Survival
16%
Overall Survival
16%
Randomized Clinical Trial
8%
Solid Malignant Neoplasm
8%
Patient Experience
8%
Drug Efficacy
8%
Clinical Trial Results
8%
Chemotherapy Agent
8%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Drug Development
100%
Lenvatinib
100%
Adverse Event
33%
Malignant Neoplasm
16%
Progression Free Survival
16%
Overall Survival
16%
Randomized Clinical Trial
8%
Solid Malignant Neoplasm
8%
Clinical Trial Results
8%
Chemotherapy Agent
8%